Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sozinibercept - Opthea

Next Previous
Drug Profile

Sozinibercept - Opthea

Alternative Names: OPT-302; soluble VEGFR-3; VGX 300

Latest Information Update: 30 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vegenics
  • Developer Opthea
  • Class Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic macular oedema
  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 31 Mar 2025 Discontinued - Phase-III for Wet age-related macular degeneration (Combination therapy, Treatment-naive) in Ukraine (Intravitreous) (NCT04757610) (EudraCT2020-004736-24)
  • 31 Mar 2025 Opthea Limited terminates the phase III ShORe trial in Wet age-related macular degeneration (Combination Therapy, Treatment-naive) the US, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, South Korea, Latvia, Malaysia, Poland, Spain, Thailand, the UK and Ukraine (Intravitreous) (NCT04757610) (EudraCT2020-004736-24)
  • 31 Mar 2025 Discontinued - Phase-II for Wet age-related macular degeneration (Monotherapy, Treatment-naive) in USA (Intravitreous)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top